Latest Breaking News On - Presentation details - Page 10 : comparemela.com

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

ATA3431 Preclinical Data Demonstrates Superior In Vivo Anti-tumor Activity, Survival, and Functional Persistence Compared to Autologous CAR-T Benchmark No Observed Treatment-Related Toxicities or.

San diegoUnited statesThousand oaksSan diego convention centerSeung sarah chaCokey nguyenAtara biotherapeutics incAmerican society of hematologySecurities exchangeExchange commissionAmerican societyAnnual meetingExecutive vice presidentChief scientificTechnical officerPresentation details

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of

United statesUnited kingdomSan diegoSan diego convention centerBaisong meiRabi hannaBroad instituteAmerican society of hematologyDivision of pediatric hematology oncologyHarvard university casEuropean hematology associationEditas medicine incBroad institute casExchange commissionDepartment of pediatric hematology oncologyAnnual congress

Editas Medicine (EDIT) Announces New EDIT-301 Safety and Efficacy Data in 17 Patients

Editas Medicine (EDIT) Announces New EDIT-301 Safety and Efficacy Data in 17 Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSan diego convention centerRabi hannaBaisong meiDepartment of pediatric hematology oncologyEuropean hematology associationAmerican society of hematologyEditas medicine incDivision of pediatric hematology oncologyEditas medicineAnnual congressAmerican societyAnnual meetingSenior vice presidentChief medical officer

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD

ATA3431 Preclinical Data Demonstrates Superior In Vivo Anti-tumor Activity, Survival, and Functional Persistence Compared to Autologous CAR-T BenchmarkNo Observed Treatment-Related Toxicities or AlloreactivityData Supports Advancement Into IND-Enabling StudiesTHOUSAND OAKS, Calif. (BUSINESS WIRE) Atara Biotherapeu.

San diegoUnited statesThousand oaksSan diego convention centerSeung sarah chaCokey nguyenAlex chapmanExchange commissionSecurities exchangeAtara biotherapeutics incCorporate communications investor relationsAmerican society of hematologyFunctional persistence comparedObserved treatment related toxicitiesAmerican societyAnnual meeting

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesUnited kingdomSan diego convention centerRabi hannaBaisong meiCristi barnettDepartment of pediatric hematology oncologyHarvard university casBroad institute casGlobenewswire incAmerican society of hematologyBroad instituteEditas medicine incExchange commissionDivision of pediatric hematology oncology